Back to search results

Stereotactic Body Radiotherapy for Centrally Located Lung Cancer

This study is testing a specific type of radiation treatment called 3-fraction stereotactic body radiotherapy (SBRT) using a dose of 45 Gray (Gy) for people with non-small cell lung cancer that is located in the center of the chest. The main goals are to see how safe this treatment is and how well it controls the cancer in the treated area. You might be able to join if you are 18 or older and have a lung tumor that is 5 cm or smaller and centrally located. The study plans to enroll 36 participants. The current status of the study is unclear.

Study design
This is an interventional study planning to enroll 36 participants with non-small cell lung cancer.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety will be measured for up to 2 years after SBRT, and local control will be measured for up to 10 years after you enroll.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04210492

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
Yale University
~36 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:45 Gray (Gy) regimen

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety of the stereotactic body radiotherapy regimen (SBRT)
Measured over From administration of SBRT up to 2 years post-SBRT
+1 more outcome measured

Conditions

Non-small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

6 sites across 1 states
Connecticut6

Study leadership

  • Henry S. Park, MD, MPH · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Henry S. Park, MD, MPH
[email protected]
203-200-2100
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Spinal cord previously irradiated to \> 40 Gy
Brachial plexus previously irradiated to \> 50 Gy
Small intestine, large intestine, or stomach previously irradiated to \> 45Gy
Brainstem previously irradiated to \> 50 Gy
Lung previously irradiated with prior V20Gy \> 35% 2. Active systemic, pulmonary, or pericardial infection 3. Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung 4. Pregnant or lactating 5. Any other medical condition or reason that, in the opinion of the investigator, would preclude study participation

What this trial measures

  • Safety of the stereotactic body radiotherapy regimen (SBRT)From administration of SBRT up to 2 years post-SBRT

    Safety will be assessed by acute (defined as within 90 days of stereotactic body radiotherapy (SBRT)) and late (from 91 days through 2 years post-SBRT) toxicities. Toxicities are based on (Common Terminology Criteria for adverse events) CTCAE v. 5 criteria

  • local control (LC) of 3-fraction stereotactic body radiotherapyUp to 10 years post-enrollment.

    The absence of primary tumor failure. Primary tumor failure is defined as Increase in tumor dimension of 20%.